Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment

Clinical and Experimental Immunology

Volumn 115, Issue 3, 1999, Pages 458-463

  Burgisser P ^a   Hammann, C ^d   Kaufmann, D ^a   Battegay, M ^b   Rutschmann, O T ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d CHUV ^*

Author keywords

Anti retroviral treatment; CD28; CD38; CD8; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; DIDANOSINE; HYDROXYUREA; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS LOAD;

ADP-RIBOSYL CYCLASE; ANTI-HIV AGENTS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HOMEOSTASIS; HUMANS; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; PROGNOSIS; SWITZERLAND; T-LYMPHOCYTE SUBSETS; VIREMIA;

EID: 0007007626     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00818.x     Document Type: Article

References (49)

1. Azuma M, Lanier LL. The role of CD28 costimulation in the generation of cytotoxic T lymphocytes. Curr Top Microbiol Immunol 1995; 198:59-74.
2. Hamann D, Baars P, Rep MHG, Hooibrink B, Kerkhofgarde SR, Klein MR, Vanlier RAW. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997; 186:1407-18.
3. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1996; 17:217-24.
4. Yang OO, Walker BD. CD8+ cells in human immunodeficiency virus type 1 pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv Immunol 1997; 66:273-311.
5. Effros RB, Allsopp R, Chiu CP et al. Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996; 10:F17-22.
6. Monteiro J, Batliwalla F, Ostrer H, Gregersen PK. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J Immunol 1996; 156:3587-90.
7. Borthwick NJ, Bofill M, Gombert WM et al. Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28- T cells. AIDS 1994; 8:431-41.
8. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland T. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 1994; 169:730-8.
9. Caruso A, Cantalamessa A, Licenziati S et al. Expression of CD28 on CD8+ and CD4+ lymphocytes during HIV infection. Scand J Immunol 1994; 40:485-90.
10. Choremi-Papadopoulou H, Viglis V, Gargalianos P, Kordossis T, Iniotaki-Theodomki A, Kosmidis J. Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr 1994; 7:245-53.
11. Landay AL, Mackewicz CE, Levy IA. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol 1993; 69:106-16.
12. Kämmerer R, Iten A, Frei PC, Bürgisser P. Expansion of T cells negative for CD28 expression in HIV infection. Relation to activation markers and cell adhesion molecules, and correlation with prognostic markers. Med Microbiol Immunol 1996; 185:19-25.
13. Saukkonen JJ, Komfeld H, Berman JS. Expansion of a CD8+/CD28- cell population in the blood and lung of HIV-positive patients. J Acquit Immune Defic Syndr 1993; 6:1194-204.
14. Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Ado Immunol 1997; 65:277-346.
15. Klenerman P, Zinkernagel RM. What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev 1997; 159:5-16.
16. Lewis DE, Tang DS, Adu-Oppong A, Schober W, Rodgers JR. Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol 1994; 153:412-20.
17. Margolick JB, Donnenberg AD. T-cell homeostasis in HIV-1 infection. Semin Immunol 1997; 9:381-8.
18. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. FASEB J 1996; 10:1408-17.
19. Deaglio S, Morra M, Mallome R et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998; 160:395-402.
20. Giorgi JV, Ho H-N, Hirji K et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994; 170:775-81.
21. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquit Immune Defic Syndr Hum Retrovir 1997; 16:83-92.
22. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. from the Los Angeles Center MACS. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993; 6:904-12.
23. Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JP, Bekesi JG. Concentrations of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers For HIV-1 infection and clinical stains. J Clin Immunol 1997; 17:185-92.
24. Kestens L, Vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, Hulstaert F, Bach BA. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 1992; 6:793-7.
25. Levacher M, Hulstaert F, Taller S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992; 90:376-82.
26. Mocroft A, Bofill M, Lipman M et al. CD8+, CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovir 1997; 14:158-62.
27. Prince HE, Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir immune Doric Syndr 1991; 4:1227-32.
28. Vanham G, Kestens L, Penne G et al. Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. J Clin Immunol 1991; 11:345-56.
29. Bouscarat F, Levacher-Clergeot M, Dazza MC, Strauss KW, Girard P-M, Ruggeri C, Sinet M. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retrovir 1996; 12:17-24.
30. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J infect Dis 1996; 173:321-9.
31. Silvestri G, Munoz C, Butini L, Bagnarelli P, Montroni M. Changes in CD8 cell subpopulations induced by antiretroviral therapy in human immunodeficiency virus infected patients. Viral Immunol 1997; 10:207-12.
32. Rutschmann OT, Opravil M, Iten A et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea for HIV infection. AIDS 1998; 12:F71-77.
33. Azuma M, Phillips JH, Lanier LL. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150:1147-59.
34. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989; 143:3183-91.
35. Funaro A, De Monte LB, Dianzani U, Forni M, Malavasi F. Human CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol 1993; 23:2407-11.
36. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76:2421-38.
37. Grossman Z, Herberman RB, Vatnik N, Intrator N. Conservation of total T-cell counts during HIV infection: alternative hypotheses and implications. J Acquir Immune Defic Syndr Hum Retrovir 1998; 17:450-7.
38. Caruso A, Licenziati S, Canaris AD et al. Contribution of CD4+, CD8+CD28+, and CD8+CD28- T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection. J Clin Invest 1998; 101:137-44.
39. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995; 95:2061-6.
40. Fiorentino S, Dalod M, Olive D, Guillet J-G, Gomard E. Predominant involvement of CD8+CD28-lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Virol 1996; 70:2022-6.
41. Rinaldo C, Huang XL, Fan ZF et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory, cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69:5838-42.
42. McMichael AJ, O'Callaghan CA. A new look at T cells. J Exp Med 1998; 187:1367-71.
43. Kern F, Ode-Hakim S, Vogt K, Hoflich C, Reinke P, Volk HD. The enigma of CD57+CD28-T cell expansion-anergy or activation? Clin Exp Immunol 1996; 104:180-4.
44. Vingerhoets JH, Vanham GL, Kestens LL et al. Increased cytolytic T lymphocyte activity and decreased B7 responsiveness are associated with CD28 down-regulation on CD8+ T cells from HIV-infected subjects. Clin Exp Immunol 1995; 100:425-33.
45. Rinaldo CR Jr, Beltz LA, Huang XL, Gupta P, Fan Z, Torpey D Jr. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res Hum Retrovir 1995; 11:481-9.
46. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dörken B. Costimulatory signals through B7.1/CD28 provera T cell apoptosis during target cell lysis. J Immunol 1997; 159:3808-15.
47. De Maria A, Colombini S, Schnittman SM, Moretta L. CD8+ cytolytic T lymphocytes become infected in vitro in the process of killing HIV-1-infected target cells. Eur J Immunol 1994; 24:531-6.
48. H2 predominance in HIV-infected individuals. Science 1994; 265:248-52.
49. Coffin JM. HIV viral dynamics. AIDS 1996; 10:S75-84.